Skip to main content
. 2010 Nov 4;15(11):1147–1158. doi: 10.1634/theoncologist.2007-0245

Table 2.

Recommended zoledronic acid and ibandronate dose reductions in patients with decreased renal function

graphic file with name onc01110-0684-t02.jpg

aDoses calculated to achieve an area under the curve of 0.66 mg-h/ml with a creatinine clearance of 75 ml/min (using Cockcroft-Gault formula). Data from zoledronic acid prescribing information [78].

bAdministration every 3 to 4 weeks. Data from ibandronate summary of product characteristics [80].

Abbreviations: ZOL, zoledronic acid; IBN, ibandronate.